





# Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics

Oscar Brunetto<sup>a</sup>, Hamilton R. Cassinelli<sup>b</sup>, Graciela Espada<sup>c</sup>, Gisela L. Viterbo<sup>d</sup> ,  
Silvia M. Meiorin<sup>e</sup>, María F. Ahumada<sup>f</sup>, Luciana Brenzoni<sup>g</sup>, María C. Maher<sup>h</sup> ,  
Ignacio Chavero<sup>i</sup>, Luis A. Ramírez Stieber<sup>j</sup> , María L. Brance<sup>k</sup> 

## ABSTRACT

**Objective.** To provide a framework for healthcare professionals managing pediatric patients who are on active glucocorticoid (GC) therapy and to develop recommendations for the prevention and treatment of GC-induced osteoporosis in the pediatric population.

**Methods.** A panel of experts on bone and pediatric diseases developed a series of PICO questions that address issues related to the prevention and treatment of osteoporosis in patients on GC therapy. In accordance with the GRADE approach, we conducted a systematic review of the literature, summarized effect estimations, and classified the quality of the evidence. Then, voting and the formulation of recommendations followed.

**Results.** Seven recommendations and six general principles were developed for GC-induced osteoporosis in the pediatric population.

**Conclusion.** These recommendations provide guidance for clinicians who must make decisions concerning pediatric patients undergoing treatment with GC.

**Keywords:** *clinical practice guidelines; glucocorticoids; osteoporosis; pediatrics.*

doi: <http://dx.doi.org/10.5546/aap.2022-02948>

**To cite:** Brunetto O, Cassinelli HR, Espada G, Viterbo GL, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics. *Arch Argent Pediatr* 2021 ; FCGC 202202948.

<sup>a</sup> Department of Endocrinology, Hospital General de Niños Pedro de Elizalde, City of Buenos Aires, Argentina; <sup>b</sup> Centro de Investigaciones Endocrinológicas Dr. César Bergadá, Hospital de Niños Dr. Ricardo Gutiérrez, City of Buenos Aires, Argentina; <sup>c</sup> Division of Rheumatology, Hospital de Niños Dr. Ricardo Gutiérrez, City of Buenos Aires, Argentina; <sup>d</sup> Department of Endocrinology, Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina; <sup>e</sup> Hospital de Niños Ricardo Gutiérrez, City of Buenos Aires, Argentina; <sup>f</sup> Hospital Provincial de Pediatría Dr. Fernando Barreyro, Posadas, Argentina; <sup>g</sup> Department of Pediatric Endocrinology, Hospital Nacional Profesor Alejandro Posadas, El Palomar, Argentina; <sup>h</sup> Instituto de Rehabilitación Psicosfísica, City of Buenos Aires, Argentina; <sup>i</sup> Sanatorio Parque, Rosario, Argentina; <sup>j</sup> Hospital Privado de Rosario, Rosario, Argentina; <sup>k</sup> Universidad Nacional de Rosario. National Scientific and Technical Research Council (Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET). Rosario, Argentina.

**Correspondence to** Oscar Brunetto: [oscar.brunetto@gmail.com](mailto:oscar.brunetto@gmail.com)

**Note:** All authors are participating on behalf of the Argentine Association of Osteology and Mineral Metabolism (Asociación Argentina de Osteología y Metabolismo Mineral, AAOMM), the Argentine Society of Osteoporosis (Sociedad Argentina de Osteoporosis, SAO), and the Argentine Society of Rheumatology (Sociedad Argentina de Reumatología, SAR) of Argentina.

**Funding:** None.

**Conflict of interest:** None.

**Received:** 12-6-2022

**Accepted:** 3-13-2023



This is an open access article under the Creative Commons Attribution–Noncommercial–Noderivatives license 4.0 International. Attribution - Allows reusers to copy and distribute the material in any medium or format so long as attribution is given to the creator. Noncommercial - Only noncommercial uses of the work are permitted. Noderivatives - No derivatives or adaptations of the work are permitted.

**Abbreviations:**

AAOMM: Argentine Association of Osteology and Mineral Metabolism  
 AP: alkaline phosphatase  
 BMC: bone mineral content  
 BMD: bone mineral density  
 DEXA: dual-energy X-ray absorptiometry  
 GC: glucocorticoids  
 GIOP: glucocorticoid-induced osteoporosis  
 GRADE: Grading of Recommendations, Assessment, Development and Evaluation  
 IOM: Institute of Medicine  
 ISCD: International Society for Clinical Densitometry  
 IV: intravenous  
 JIA: juvenile idiopathic arthritis  
 PICO: Patient-Intervention-Comparison-Outcome  
 PTH: parathyroid hormone  
 RevMan: Review Manager  
 SAO: Argentine Society of Osteoporosis  
 SAR: Argentine Society of Rheumatology  
 SD: standard deviation  
 SLE: systemic lupus erythematosus  
 TBLH: total body less head  
 TRP: tubular reabsorption of phosphate  
 VFA: vertebral fracture assessment  
 VF: vertebral fractures

**INTRODUCTION**

While 60% of the peak bone mass acquisition is genetic, it is also influenced by multiple factors, such as nutritional status, calcium and vitamin D intake, physical activity, mobility, exposure to medications, chronic inflammation, and pubertal development.<sup>1</sup>

GIOP is one of the most common secondary causes. An adverse effect of long-term GC therapy is a reduction in BMD and/or an increase in the prevalence of brittle or osteoporotic fractures.<sup>2-5</sup> Bone mass loss, with predominant involvement of cancellous bone, ranges between 10% and 40% depending on the site examined, duration of treatment, underlying disease and GC used, dose and exposure time.<sup>6-8</sup> Fracture risk increases rapidly after initiation of GC treatment, followed by a slow but continuous phase, which reverts rapidly upon discontinuation of treatment.<sup>9</sup>

For this reason, to reduce the incidence of brittle fractures, an early intervention and specific measures to prevent their occurrence are required. One of the strategies in prevention is to maximize, as much as possible, the peak bone mass with targeted interventions during childhood and adolescence, taking advantage of

this window of opportunity to minimize the risk of fractures.

Few studies have been conducted on GIOP prevention and treatment in pediatrics. Therefore, the theoretical framework was developed under the descriptive narrative methodology. These recommendations were made according to the GRADE methodology.

**OBJECTIVES**

To provide evidence-based recommendations for the prevention and treatment of GIOP in children under 18 years of age on GC therapy for more than 3 months.

**Target audience**

Healthcare professionals involved in the care of patients on GC therapy.

**PREVALENCE OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN CHILDREN AND ADOLESCENTS**

Decreased bone mass in children may increase the risk of fractures in childhood and, potentially, in adulthood as a result of suboptimal peak bone mass.<sup>10-15</sup> Other studies have evidenced the development of vertebral and long bone fractures, with a prevalence ranging between 10% and 34%.<sup>16,17</sup>

In the past decade, observational studies, including the Canadian steroid-induced osteoporosis in the pediatric population (STOPP) study, have revealed key clinical-biological principles regarding GIOP.<sup>18</sup>

Compeyrot-Lacassagne et al. studied patients with SLE and found that the prevalence of osteopenia was 37.5% and that of osteoporosis, 20.3%. However, they defined osteopenia as a Z-score between  $\leq -1$  and  $\geq -2.5$ , and osteoporosis, as a Z-score  $< -2.5$ , as per a DEXA scan.<sup>15</sup> Other authors observed that 19% of patients had VF, with an average of 2.9 fractures per patient; of these, 56% were asymptomatic.<sup>17</sup>

Another study conducted in patients with rheumatic disease found a 12.4% incidence of fractures at 3 years, which was higher in the first year and was associated with a two-fold increase in the risk of fractures per 0.5 mg/kg of increase in the daily average GC dose.<sup>18</sup>

Marstein et al. studied bone mass in patients stratified into 2 groups by age ( $< 20$  and  $\geq 20$  years old).<sup>19</sup> In the first group, they demonstrated a negative correlation between prednisolone (use at follow-up, monthly, and cumulative dose)

and lumbar spine Z-score, and with inflammatory markers.

The extent of involvement in bone mass depends on several factors. The decrease in Z-score as per the bone density scan in the first 6 months after starting GC therapy is another predictor of bone involvement.<sup>18</sup>

## DIAGNOSIS

### Osteoporosis in children and adolescents

A DEXA scan to assess BMD is the most adequate method for children and adolescents as per the ISCD 2019.<sup>20</sup>

Regions considered for assessment include the posterior-anterior spine (L1–L4) and TBLH.

Unlike in the adult population, the diagnosis of osteoporosis in children and adolescents should not be made solely on the basis of a bone densitometry value. In this population, it is also necessary to consider the presence of brittle fractures. Thus, the finding of 1 or more vertebral compression fractures is suggestive of osteoporosis in the absence of local disease or high energy trauma that could account for it.

In the absence of a VF, the presence of 2 or more long bone brittle fractures before 10 years old or 3 or more long bone fractures before 19 years old and a BMD with a Z-score  $\leq -2.0$  is indicative of osteoporosis in children and adolescents (*Table 1*).

For the assessment of bone health in pediatrics, it is necessary to combine the medical history and the study methodology, which can be summarized as follows:

- Medical history: anthropometry, pubertal stage.
- History and comorbidities.
- Other secondary causes.
- Lab test for phosphocalcic metabolism (*Table 2*).

- History of brittle fractures of long bones.
- X-ray of dorsal/lumbar spine or VFA.
- BMD.

### Vertebral fractures

A lateral plain X-ray of the dorsolumbar spine is recommended to assess vertebral fractures. The current ISCD 2019 recommendations suggest that VFA using DEXA may replace the X-ray of the spine to assess VF.<sup>20</sup> In both cases, the recommended method for vertebral morphometry is Genant's semi-quantitative criteria.<sup>21</sup> In cases in which some vertebrae cannot be technically assessed by VFA or in which X-ray findings are not typical of an osteoporotic VF (suspicion of destructive inflammatory or malignant processes, congenital malformations, misalignments, or others), the recommendation is to perform another imaging study such as, for example, magnetic resonance imaging.

### Follow-up densitometry

A DEXA bone densitometry should be performed every 6–12 months, depending on each patient. It is important to remember that, in children with short stature or stunted growth, the BMD and BMC of the spine and TBLH results should be adjusted for an adequate interpretation, using the height Z-score.

## PREVENTION AND TREATMENT RECOMMENDATIONS

### Methodology

The prevention and treatment recommendations were developed based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology ([www.gradeworkinggroup.org](http://www.gradeworkinggroup.org)) (*Supplementary material 1*).<sup>22</sup>

**TABLE 1. Interpretation of bone mineral density in pediatrics**

#### OSTEOPOROSIS

Presence of 1 or more brittle vertebral fractures.

Presence of 2 or more brittle fractures of long bones before 10 years old and BMD with a Z-score  $\leq -2.0$ .

Presence of 3 or more fractures of long bones before 19 years old and BMD with a Z-score  $\leq -2.0$ .

#### LOW BONE MASS OR LOW BONE MINERAL DENSITY

Presence of a BMC or BMD with a Z-score below  $-2.0$  SD.

BMD: bone mineral density.

BMC: bone mineral content.

SD: standard deviation.

**TABLE 2. Biochemical tests to assess phosphocalcic metabolism**

Complete blood count, erythrocyte sedimentation rate, CRP
Uremia, blood creatinine level, creatinine clearance
Liver function tests
Anti-transglutaminase antibodies, anti-endomysial antibodies, anti-gliadin antibodies
Serum IgA level
TSH Free T4
Total and ionized calcium levels, blood albumin level, blood phosphate level, blood magnesium level AP PTH
Vitamin 25(OH)D level
24-hour urine: urine calcium level, urine creatinine level, urine phosphate level, TRP

CRP: C-reactive protein.

Ab: antibodies.

IgA: immunoglobulin A.

TSH: thyroid stimulating hormone.

T4: thyroxine.

AP: alkaline phosphatase.

PTH: parathyroid hormone.

TRP: tubular reabsorption of phosphate.

**Participation.** These recommendations were developed by experts on account of the following Argentine scientific societies: AAOMM, SAO, and SAR (*Supplementary material 2*).

**Literature search.** The search was done in MEDLINE/PubMed, Cochrane Library, and LILACS since the beginning of each database until April 30<sup>th</sup>, 2021 (*Supplementary material 3*).

**Study selection.** The Rayyan software (<https://rayyan-prod.qcri.org/>) was used to screen literature search results. Selected articles were related to the corresponding PICO questions (*Supplementary material 4*).<sup>22</sup>

**Data extraction and analysis.** The Review Manager (RevMan) software, V.5.4.1, was used for data extraction and grouping for the statistical analysis.

**Evidence reporting.** Data were exported to the GRADEpro GDT software (<https://grade.pro.org/>) to develop the GRADE tables (*Supplementary material 5*) for each PICO question. Two independent reviewers assessed the quality of evidence for each result using the GRADE quality assessment criteria.<sup>22</sup>

The GRADE approach rates the quality of evidence into 4 levels (high, moderate, low, or very low). In the case of a recommendation made by expert opinion consensus in the absence of evidence, the recommendation was rated as very low quality.

**Rigor of development.** These recommendations have been developed according to the GRADE methodology and comply with the AGREE reporting checklist to ensure the completeness and transparency of

reports. A recommendation may be for or against the proposed intervention and be rated as strong or conditional.<sup>21</sup>

**From evidence to recommendations.** The GRADE methodology specifies that the expert panel makes recommendations based on the balance of benefits and harms, the quality of the evidence, and the values and preferences of parents/patients.

**Consensus development.** The voting panel voted on the direction and strength of the recommendation for each PICO question. The recommendations required an agreement level above 70%.<sup>23</sup> In some cases, the voting panel combined the PICO questions into a single recommendation for clarity. Some PICO questions were removed because the evidence was insufficient for a formal recommendation.

## RESULTS

The literature review identified 361 articles; of these, only 12 scientific articles met the inclusion criteria for analysis (*Supplementary material 6*). A total of 7 recommendations (*Table 3*) and 6 general principles were developed (*Table 4*).

## PREVENTION AND TREATMENT RECOMMENDATIONS

**Recommendation 1.** Calcium and vitamin D are strongly recommended over placebo in children and adolescents on oral GC treatment, both for prevention and in those under treatment.

Calcium and vitamin D supplementation is strongly recommended in patients on GC treatment, both for prevention and in those under

treatment for osteoporosis. This is a strong recommendation, despite the quality of the evidence, because the clinical experience and the indirect evidence support the benefits of adding these supplementation options.<sup>24–26</sup>

Chronic calcium deficiency resulting from inadequate intake or poor intestinal absorption is a major cause of reduced bone mass, as well as being important for peak bone mass.<sup>27,28</sup> Patients with a low dietary intake may increase it by consuming calcium-rich foods; supplementation should be considered when intake is insufficient (Table 5).<sup>29</sup>

Moreover, it is known that vitamin D plays an important role in calcium homeostasis and muscle function, among others.<sup>30</sup> The co-administration of calcium and vitamin D is superior to their administration separately.

This panel recommends measuring vitamin D levels; it is important to know calcemia and calciuria values in order to establish the best form of administration in each case.

**Recommendation 2.** *The administration of vitamin D (on a daily/weekly/monthly basis, as applicable) is strongly recommended in children and adolescents on oral GC treatment, both for prevention and in those under treatment.*

The suggested dose, depending on the child's or adolescent's age and vitamin D levels, is twice the dose required for the patient's age and physiological situation according to the IOM recommendations.<sup>31</sup>

For an adequate supplementation, the patient's age, place of residence, type of nutrition, other medical history related to phosphocalcic metabolism, and plasma vitamin D levels should be taken into account. Physicians should differentiate whether the patient has deficient or normal plasma levels, and provide supplementation accordingly.<sup>32</sup> Daily or weekly doses may be used for maintenance. These are safe doses, i.e. the likelihood of hypercalciuria is low. In pubertal children, monthly doses may be indicated if there are no contraindications.

In patients with deficiency, a new vitamin D measurement is useful. If conditions are stable, annual vitamin D measurement is recommended. Vitamin D<sub>3</sub> is preferred given its longer half-life.

This recommendation arises from the combination of PICO questions in the face of daily, weekly, and monthly doses at different dosages.<sup>33</sup>

**Recommendation 3.** *Physical activity*

**TABLE 3. Recommendations for patients on treatment with supraphysiological doses of GC (> 8 mg m<sup>2</sup>/day of hydrocortisone or equivalent) for more than 3 months**

Recommendations	Level of evidence
1. Calcium and vitamin D are strongly recommended over placebo in children and adolescents on oral GC treatment, both for prevention and in those under treatment for osteoporosis.	Very low
2. The administration of vitamin D (on a daily/weekly/monthly basis, as applicable) is strongly recommended in children and adolescents on oral GC treatment, both for prevention and in those under treatment for osteoporosis.	Very low
3. Physical activity (adequate to the underlying condition) is recommended in children and adolescents on oral GC treatment. <i>Expert opinion.</i>	Very low*
4. Alendronate is conditionally recommended over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.	Moderate to very low
5. Risedronate is conditionally recommended over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.	Moderate to low
6. Pamidronate is conditionally recommended over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.	Very low
7. Zoledronic acid is suggested over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis. <i>Expert opinion.</i>	Very low*

\* This recommendation is based on the consensus of expert opinion due to the absence of evidence; for this reason, it is classified as very low quality.

**TABLE 4. General principles**

Number	General principles
1	An adequate clinical follow-up of the growth and development of patients on GC treatment, an adequate management of associated conditions, especially autoimmune diseases, diabetes mellitus, sarcopenia, endocrine diseases, and any other condition that may affect bone metabolism, is recommended. Also, an adequate management of other medications that could affect bone metabolism (beyond GC).
2	The gold standard method to assess BMD study is a DEXA bone densitometry, which should be performed every 6 to 12 months as long as patients remain on GC treatment or persist on GIOP treatment.
3	Biochemical assessment of bone metabolism together with an assessment of vertebral fractures is as important as BMD assessment.
4	GIOP treatment should be based on shared decisions and preferences between the parents/patient and the treating physician once the different therapeutic options available, costs, route of administration, and possible adverse effects are known.
5	The goal of GIOP treatment is to prevent the occurrence of new brittle fractures, as well as to increase BMD, as an optimal situation.
6	Treatment with GC should be limited to the minimum effective dose possible for the shortest time possible.

BMD: bone mineral density.

DEXA: dual-energy X-ray absorptiometry.

GC: glucocorticoids.

GIOP: glucocorticoid-induced osteoporosis.

**TABLE 5. Recommendations by the Institute of Medicine (IOM) about calcium and vitamin D use in pediatrics (as modified by the IOM)<sup>31</sup>**

Age group	Calcium (mg/day)		Vitamin D (IU/day)	
	Recommendation	Maximum use allowed	Recommendation	Maximum use allowed
0–6 months	200	1000	400	1000
6–12 months	260	1500	400	1500
1–3 years	700	2500	600	2500
4–8 years	1000	2500	600	3000
≥ 9 years	1300	3000	600	4000

(according to the underlying condition) is recommended over no physical activity in children and adolescents on oral GC treatment.

Lifestyle changes influence the acquisition of peak bone mass by 20–40%.<sup>27,28</sup> Changes in bone structure and composition take place during puberty and up to 30 years of age, thus influencing bone strength. It is important to understand the factors that affect bone strength early in life because a low bone strength is associated with an increased risk of fractures later in life, regardless of the incidence of falls.<sup>34,35</sup> The expert panel recommends physical activity based on the patient's age, current clinical condition

(fracture pain), and underlying conditions, despite the lack of evidence in the literature in the pediatric population on GC treatment.

*Recommendation 4. Alendronate is conditionally recommended over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.*

There are no studies providing sufficient evidence on the use of alendronate to prevent bone loss in children on GC treatment; however, there is sufficient evidence in relation to patients who require treatment.<sup>36–39</sup> In spite of this, in patients who already have a fracture, IV bisphosphonates are preferred because

of their greater efficacy in fracture repair and improvement of associated pain. If it is not possible to use IV bisphosphonates due to their cost or availability, oral bisphosphonates may be an option. For this reason, this is a *conditional* recommendation.

*Recommendation 5. Risedronate is conditionally recommended over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.*

Further investigations on risedronate for GIOP are required. A study demonstrated an increase in lumbar spine BMD in patients treated with CG.<sup>40</sup> As mentioned above, in patients who already have a fracture, IV bisphosphonates are preferred; oral bisphosphonates are an option in cases of non-availability.

*Recommendation 6. Pamidronate is conditionally recommended over calcium and vitamin D only in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.*

Few data are currently available on bisphosphonates and their use in pediatrics, and even less on IV bisphosphonate use in this population. Most of the experience regarding the safety and effectiveness of pamidronate has been reported in patients with osteogenesis imperfecta. Glorieux et al. reported that the bone mass of pediatric patients with osteogenesis imperfecta increased significantly with IV pamidronate, with

no negative effects on growth.<sup>41</sup> Due to the low/moderate quality of the evidence of published studies, the administration of pamidronate is recommended in the study population with osteoporosis and on GC therapy.

*Recommendation 7. Zoledronic acid is suggested over placebo in children and adolescents on chronic oral GC treatment, diagnosed with osteoporosis.*


No studies have been conducted in pediatric patients with GIOP and fractures and treatment with zoledronic acid. The pediatric experience with zoledronic acid is based mainly on its use in patients with osteogenesis imperfecta versus other bisphosphonates<sup>44-46</sup> and on retrospective studies,<sup>47,48</sup> both in children and adults with osteogenesis imperfecta, and it has demonstrated to reduce osteoporotic fractures. For this reason, the expert panel suggests using zoledronic acid in patients with fractures.

Figure 1 shows the prevention and treatment algorithm recommended for the pediatric population.

## DISCUSSION

GCs are used in a wide variety of diseases in children and adolescents, and several studies have shown adverse effects on bone mass and growth.<sup>49</sup> GIOP is a condition that causes important alterations in the quality of life; the clinical condition represents the effect of the underlying disease in addition to the direct and

FIGURE 1. Patient younger than 18 years on glucocorticoid treatment



indirect harmful effects of GC on the skeleton. We believe that prospective, controlled studies are required to assess the results of prevention and osteoactive treatment in children and adolescents receiving chronic GC treatment. The basis of current treatment is the prevention of bone involvement and ensuring that the patient achieves adequate levels of daily calcium intake, vitamin D supplementation, and physical activity, all in the context of adequate clinical management of the patient's baseline condition and a rational use of GC. In addition, it is worth noting the importance of systematic monitoring of bone health in this population through the use of imaging techniques and lab test controls. The latter allows to detect and characterize bone involvement early and, at the same time, establish therapeutic measures aimed at improving it.

In cases of established osteoporosis, i.e. patients with the presence of brittle fractures, IV bisphosphonates are the medication of choice for treatment. It is critical to limit the long-term use of GC to the minimum effective dose and the shortest duration possible.

## CONCLUSIONS

These recommendations provide guidance for physicians who must make decisions for pediatric patients on GC therapy. ■

## Acknowledgments

We would like to thank Rubén Abdala and Betiana Pérez for their help with the systematic search of the literature, and Natalia Zamora for conducting the voting.

Supplementary material available at: [https://www.sap.org.ar/docs/publicaciones/archivosarg/2024/2948\\_AE\\_Brunetto\\_Anexo.pdf](https://www.sap.org.ar/docs/publicaciones/archivosarg/2024/2948_AE_Brunetto_Anexo.pdf)

## REFERENCES

- Rabinovich CE. Bone mineral status in juvenile rheumatoid arthritis. *J Rheumatol Suppl.* 2000; 58:34-7.
- O'Sullivan S, Grey A. Adverse skeletal effects of drugs - beyond Glucocorticoids. *Clin Endocrinol (Oxf).* 2015; 82(1):12-22.
- Grover M, Bachrach LK. Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment. *Curr Osteoporos Rep.* 2017; 15(4):271-82.
- Dussault PM, Lazzari AA. Epilepsy and osteoporosis risk. *Curr Opin Endocrinol Diabetes Obes.* 2017; 24(6):395-401.
- Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. *Curr Opin Rheumatol.* 2016; 28(4):420-5.
- Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int.* 2007; 18(10):1319-28.
- Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. *Osteoporos Int.* 2005; 16(12):2168-74.
- Bianchi ML. Causes of secondary pediatric osteoporosis. *Pediatr Endocrinol Rev.* 2013; 10(Suppl 2):424-36.
- van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int.* 2002; 13(10):777-87.
- Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. *J Rheumatol.* 2005; 32(4):729-33.
- Huber AM, Gaboury I, Cabral DA, Lang B, et al. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. *Arthritis Care Res (Hoboken).* 2010; 62(4):516-26.
- Stagi S, Masi L, Capannini S, Cimaz R, et al. Cross-sectional and longitudinal evaluation of bone mass in children and young adults with juvenile idiopathic arthritis: the role of bone mass determinants in a large cohort of patients. *J Rheumatol.* 2010; 37(9):1935-43.
- Haugen M, Lien G, Flatø B, Kvammen J, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. *Arthritis Rheum.* 2000; 43(7):1504-10.
- Lien G, Flatø B, Haugen M, Vinje O, et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. *Arthritis Rheum.* 2003; 48(8):2214-23.
- Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. *Arthritis Rheum.* 2007; 56(6):1966-73.
- Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. *Rheumatol Int.* 1998; 18(2):45-9.
- Nakhla M, Scuccimarri R, Duffy KN, Chédeville G, et al. Prevalence of vertebral fractures in children with chronic rheumatic diseases at risk for osteopenia. *J Pediatr.* 2009; 154(3):438-43.
- LeBlanc CM, Ma J, Taljaard M, Roth J, et al. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients with Rheumatic Disorders. *J Bone Miner Res.* 2015; 30(9):1667-75.
- Marstein HS, Godang K, Flatø B, Sjaastad I, et al. Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study. *Pediatr Rheumatol Online J.* 2021; 19(1):56.
- Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. *J Clin Densitom.* 2019; 22(4):453-71.
- Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res.* 1993; 8:1137-48.
- Guyatt G, Oxman AD, Akl EA, Kunz R, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* 2011; 64(4):383-94.
- Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, et al. Use of GRADE grid to reach decisions on clinical practice



- guidelines when consensus is elusive. *BMJ*. 2008; 337:a744.
24. Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. *Pediatr Nephrol*. 2006; 21(3):350-4.
  25. Choudhary S, Agarwal I, Seshadri MS. Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study. *Pediatr Nephrol*. 2014; 29(6):1025-32.
  26. Yadav VK, Sharma S, Debata PK, Patel S, et al. Change in Bone Mineral Density and Role of Vitamin D and Calcium Supplementation During Treatment of First Episode Nephrotic Syndrome. *J Clin Diagn Res*. 2017; 11(9):SC18-21.
  27. Baxter-Jones ADG, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass. *J Bone Miner Res*. 2011; 26(8):1729-39.
  28. Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. *Osteoporos Int*. 2016; 27(4):1281-386. Erratum in: *Osteoporos Int*. 2016; 27(4):1387.
  29. Palermo A, Naciu AM, Tabacco G, Manfrini S, et al. Calcium citrate: from biochemistry and physiology to clinical applications. *Rev Endocr Metab Disord*. 2019; 20(3):353-64.
  30. Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007; 357(3):266-81.
  31. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Washington (DC): National Academies Press (US); 2011.
  32. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011; 96(7):1911-30. Erratum in: *J Clin Endocrinol Metab*. 2011; 96(12):3908.
  33. Lima GL, Paupitz JA, Aikawa NE, Alvarenga JC, Pereira RMR. A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus: positive effect on trabecular microarchitecture using HR-pQCT. *Osteoporos Int*. 2018; 29(3):587-94.
  34. Kelsey JL, Browner WS, Seeley DG, Nevitt MC, Cummings SR. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. *Am J Epidemiol*. 1992; 135(5):477-89.
  35. Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A. Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. *Nephrol Dial Transplant*. 2005; 20(8):1598-603.
  36. Bianchi ML, Cimaz R, Bardare M, Zulian F, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. *Arthritis Rheum*. 2000; 43(9):1960-6.
  37. Bianchi ML, Colombo C, Assael BM, Dubini A, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. *Lancet Respir Med*. 2013; 1(5):377-85.
  38. Inoue Y, Shimojo N, Suzuki S, Arima T, et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. *Clin Rheumatol*. 2008; 27(7):909-12.
  39. Rudge S, Hailwood S, Horne A, Lucas J, et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. *Rheumatology (Oxford)*. 2005; 44(6):813-8.
  40. Rooney M, Bishop N, Davidson J, Beresford MW, et al. The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. *E Clinical Medicine*. 2019; 12:79-87.
  41. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. *N Engl J Med*. 1998; 339(14):947-52.16.
  42. Noguera A, Ros JB, Pavia C, Alcover E, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. *J Pediatr Endocrinol Metab*. 2003; 16(4):529-36.
  43. Brown JJ, Zacharin MR. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. *J Paediatr Child Health*. 2005; 41(11):580-2.
  44. Glorieux F, Devogelaer N, Bishop N, Bober M, et al. Intravenous zoledronic acid (zol) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI). *Calcif Tissue Int*. 2008; 82:S85.
  45. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. *J Pediatr Endocrinol Metab*. 2012; 25(5-6):485-91.
  46. Lv F, Liu Y, Xu X, Song Y, et al. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. *Endocr Pract*. 2018; 24(2):179-88.
  47. Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zoledronic acid in children with type III osteogenesis imperfecta. *J Bone Miner Metab*. 2010; 28(4):451-5.
  48. Vuorimies I, Toiviainen-Salo S, Hero M, Mäkitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. *Horm Res Paediatr*. 2011; 75(5):346-53.
  49. Laan RF, Buijs WC, van Erning LJ, Lemmens JA, et al. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. *Calcif Tissue Int*. 1993; 52(1):5-9.